Trimethoprim-Sulfamethoxazole Dosing for Children
For children, the recommended dose of trimethoprim-sulfamethoxazole is 8-12 mg/kg/day based on the trimethoprim component, divided into 2 doses for oral administration or 4 divided doses for intravenous administration. 1, 2, 1
Standard Dosing by Indication
For Skin and Soft Tissue Infections (SSTI)
- Oral dosing: 8-12 mg/kg/day (based on trimethoprim component) in 2 divided doses 1
- IV dosing: 8-12 mg/kg/day (based on trimethoprim component) in 4 divided doses 1
- Maximum adult dose: 1-2 double-strength tablets twice daily (equivalent to 320 mg trimethoprim/1600 mg sulfamethoxazole per day)
For Serious Infections (Catheter-Related, Sepsis)
- Mild-to-moderate infections: 6-12 mg TMP/kg/day in divided doses every 12 hours 3
- Serious infections: 15-20 mg TMP/kg/day in divided doses every 6-8 hours 3
For Pneumocystis Pneumonia (PCP) Prophylaxis
- Prophylaxis dose: 150 mg TMP with 750 mg SMX per m² body surface area per day, divided into 2 doses, given 3 days per week 4
- Total daily dose should not exceed 320 mg TMP with 1600 mg SMX 4
- Alternative: 8-12 mg/kg/day (TMP component) in 2 divided doses for continuous prophylaxis 5
For Pertussis Treatment (Alternative Agent)
- Children >2 months: Trimethoprim 8 mg/kg per day, sulfamethoxazole 40 mg/kg per day in 2 divided doses for 14 days 6
- Contraindicated in infants <2 months due to kernicterus risk 6
For Urinary Tract Infections
- Treatment: 10 mg/kg trimethoprim plus 40 mg/kg sulfamethoxazole twice daily for 5 days 7
- Prophylaxis: 2 mg/kg trimethoprim with 10 mg/kg sulfamethoxazole once daily at bedtime 8
Important Clinical Considerations
Age Restrictions
TMP-SMX is contraindicated in infants younger than 2 months of age due to the risk of kernicterus from sulfamethoxazole displacing bilirubin from protein binding sites 1, 9. This is a critical safety concern that must not be overlooked.
Renal Function Adjustments
Dosing must be adjusted in patients with impaired renal function, as both components are primarily eliminated by the kidneys 9. The half-lives of both sulfamethoxazole (10 hours) and trimethoprim (8-10 hours) are significantly prolonged in renal insufficiency 9.
Monitoring Requirements
- Complete blood counts should be performed at initiation and monthly intervals to assess for hematologic toxicity, particularly neutropenia and thrombocytopenia 4
- Serum creatinine monitoring is essential as creatinine clearance significantly affects drug clearance 10, 11
- Elderly patients and those with folate deficiency are at higher risk for bone marrow suppression 9
Common Pitfalls to Avoid
Dosing confusion: Always dose based on the trimethoprim component, not the sulfamethoxazole component, as this is the standard reference 1, 3
Inadequate dosing in serious infections: For severe infections like osteomyelitis, higher doses (12-16 mg/kg/day TMP) may be needed 12, 13. Recent pharmacokinetic data suggests 8 mg/kg/day divided every 12 hours matches adult exposure and achieves therapeutic targets for organisms with MIC ≤0.5 mg/L 10
Overlooking adverse effects: TMP-SMX has a higher rate of adverse events compared to alternative agents, particularly rash, gastrointestinal symptoms, and hematologic toxicity 13, 14. In one pediatric study, 41% of patients experienced adverse events 13
Drug interactions: TMP-SMX potentiates oral hypoglycemics, increases digoxin levels (especially in elderly), and can cause hyperkalemia when combined with ACE inhibitors 9
Resistance considerations: While bactericidal and effective against most MRSA strains, efficacy data for some indications remain limited 1. Always obtain cultures when possible to guide therapy.
The 8-12 mg/kg/day dosing range (based on trimethoprim) divided into 2 oral doses or 4 IV doses represents the consensus recommendation across multiple high-quality guidelines for most pediatric infections 1, 2, 1, 3.